Preliminary results from ERAS-007 plus encorafenib and cetuximab (EC) in patients (pts) with metastatic BRAF V600E mutated colorectal cancer (CRC) in HERKULES-3 study: A phase 1b/2 study of agents targeting the mitogen-activated protein kinase (MAPK) pathway in pts with advanced gastrointestinal malignancies (GI cancers)

Authors
Category Primary study
JournalJournal of Clinical Oncology
Year 2023
This article has no abstract
Epistemonikos ID: 0bfe8e2c063e974f9a932db3cd3243b449581f8d
First added on: Feb 16, 2025